Stella Diagnostics and Mayo Clinic to Present Data on the Utility of the STLA101 Test for Esophageal Cancer Staging at the 2022 AGA Digestive Disease Week Conference SALT LAKE CITY, May 11, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and...

Stella Diagnostics Announces Leadership Changes: Dr. Joe Abdo Assumes a New Role as Chief Scientific Officer, and Director David Seaburg is Appointed Chief Executive Officer SALT LAKE CITY, April 22, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and...

Stella Diagnostics Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting SALT LAKE CITY, April 06, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and...

Stella Diagnostics to Present at “Next Big Thing” Session at Society of American Gastroenterologists and Endoscopic Surgeons Annual Meeting Stella Diagnostics Designated as a Semi-Finalist for SAGES Shark Tank 2022Stella Diagnostics and Collaborators to Give a Clinical Science Data Presentation at Major Medical Conference in Denver ...

Stella Diagnostics Named ‘Best Clinical Proteomics Solution’ of 2021 by Biotech Breakthrough Awards SALT LAKE CITY, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and...